This approach was chosen due to the substantial differences in cancer risk profiles between BRCA2 and BRCA1, as well as the greater number of BRCA2 P/LP carriers in the UK Biobank, which allowed for increased statistical power. This evidence concerns the gene BRCA1 and cancer.